| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenue | 656,606 | 231,608 | 335,319 | 312,164 |
| Cost of goods sold | 1,096,606 | 852,818 | 837,926 | 668,322 |
| Gross loss | -440,000 | -621,210 | -502,607 | -356,158 |
| Rent | - | - | 1,045 | 1,099 |
| Depreciation | 0 | 0 | - | - |
| General and administrative | 145,444 | 75,952 | 27,711 | - |
| Payroll and consulting fees | 0 | 0 | - | - |
| Professional fees | 115,990 | 88,219 | 136,337 | 64,075 |
| Payroll and consulting fees | - | - | - | 25,389 |
| General and administrative | - | - | - | 51,225 |
| Royalty expense | 234,212 | 55,599 | - | - |
| Total operating expenses | 495,646 | 219,770 | 165,093 | 141,788 |
| Change in the fair value of obligation to issue shares | - | - | - | 1,324,327 |
| Loss from operations | -935,646 | -840,980 | -667,700 | -497,946 |
| Change in the fair value of derivative conversion feature | 7,296 | 46,438 | 641,711 | -6,216 |
| Change in the fair value of obligation to issue shares | 168,355 | 46,033 | - | - |
| Foreign exchange gain (loss) | 24,243 | 85,442 | - | - |
| Interest expense | 506,331 | 657,515 | 615,516 | 631,744 |
| Imputed interest expense | 187,242 | - | - | - |
| Loss on the extinguishment of debt | 0 | 0 | - | - |
| Change in the fair value of obligation to issue shares | - | - | 1,880,911 | - |
| Other expense | 0 | 0 | 1,930,000 | - |
| Total other income (expenses) | -542,165 | -572,478 | -22,894 | 686,367 |
| Net income (loss) | -1,477,811 | -1,413,458 | -690,594 | 188,421 |
| Foreign currency translation adjustment | 278,300 | -653,505 | -6,891 | -104,442 |
| Net comprehensive income (loss) | -1,199,511 | -2,066,963 | -697,485 | 83,979 |
| Diluted average shares | - | - | - | 662,501,405 |
| Basic and diluted income (loss) per share of common shares | 0 | 0 | 0 | 0 |
| Weighted average number of shares outstanding | 662,501,405 | 662,501,405 | 662,501,405 | - |
CANNAPHARMARX, INC. (CPMD)
CANNAPHARMARX, INC. (CPMD)